Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating
patients with classical Hodgkin lymphoma that has come back (relapsed). Brentuximab vedotin
is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab
attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them.
Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma
cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant
treatment and spare the considerable cost and toxicity on transplantation.